Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:15 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 7,083 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Completed Not applicable Interventional

Developing a Psychosexual Educational Partners Program: PEPP A Feasibility Study

NCT05070299
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
Psychosexual Educational Partner Program (PEPP)
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Nov 3, 2026, 1:15 PM EST
Enrolling by invitation Phase 3 Interventional

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

NCT05645536
View directory record Official record
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 51 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
17
States / cities
Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 1:15 PM EST
Recruiting Not applicable Interventional

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

NCT04968964
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
DiviTum® TKa assay, Study Care Plans
Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 3, 2026, 1:15 PM EST
Completed No phase listed Observational

Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors

NCT00369109
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Pancreatic Cancer
Interventions
biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Nov 3, 2026, 1:15 PM EST
Terminated Phase 1 Interventional

A Study of MLN8054 in Patients With Advanced Solid Tumors

NCT00249301
View directory record Official record
Conditions
Breast Neoplasm, Colon Neoplasm, Pancreatic Neoplasm, Bladder Neoplasm
Interventions
MLN8054
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Nov 3, 2026, 1:15 PM EST
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

NCT04711109
View directory record Official record
Conditions
BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
Interventions
Denosumab, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
47
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 3, 2026, 1:15 PM EST
Suspended Phase 1 Interventional

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

NCT05958199
View directory record Official record
Conditions
Metastatic Malignant Neoplasm
Interventions
NPX267
Drug
Lead sponsor
NextPoint Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Nov 3, 2026, 1:15 PM EST
Completed Phase 2 Interventional

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

NCT00004157
View directory record Official record
Conditions
Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, recombinant interleukin-11
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Nov 3, 2026, 1:15 PM EST
Active, not recruiting Phase 1 Interventional

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

NCT01327781
View directory record Official record
Conditions
HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 3, 2026, 1:15 PM EST
Suspended Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications

NCT03845907
View directory record Official record
Conditions
Breast Cancer
Interventions
Gen 1B, Gen 1
Device
Lead sponsor
Seno Medical Instruments Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Nov 3, 2026, 1:15 PM EST
Terminated Phase 2 Interventional Results available

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

NCT02124902
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Docetaxel, Carboplatin, FDG-PET/MR
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Nov 3, 2026, 1:15 PM EST
Completed Phase 3 Interventional Results available

Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

NCT00393939
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sunitinib malate, Taxotere
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Berkely, California • Shreveport, Louisiana • Beaumont, Texas + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Nov 3, 2026, 1:15 PM EST
Completed Phase 1 Interventional

Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1

NCT00968656
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Diffuse Large B-cell Lymphoma
Interventions
PET/CT, Laboratory Testing, Safety Testing, Immunohistochemistry staining, F-18-ISO
Radiation · Other · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Nov 3, 2026, 1:15 PM EST
Completed No phase listed Observational

Compliance to a Hormone Therapy Regimen in Breast Cancer

NCT00666822
View directory record Official record
Conditions
Breast Cancer
Interventions
compliance monitoring, medical chart review, questionnaire administration
Behavioral · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Nov 3, 2026, 1:15 PM EST
Completed Phase 2 Interventional Results available

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

NCT01763931
View directory record Official record
Conditions
Breast Cancer
Interventions
Digoxin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Nov 3, 2026, 1:15 PM EST
Completed No phase listed Observational

Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer

NCT00161265
View directory record Official record
Conditions
Breast Cancer
Interventions
tissue procurement
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Nov 3, 2026, 1:15 PM EST
Completed No phase listed Observational

Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer

NCT02125019
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Nov 3, 2026, 1:15 PM EST
Completed No phase listed Observational

Morphine for the Treatment of Pain in Patients With Breast Cancer

NCT00003000
View directory record Official record
Conditions
Pain
Interventions
fentanyl citrate, morphine sulfate
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Nov 3, 2026, 1:15 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Improving Cancer Family Caregivers' Knowledge and Communication About Care Options

NCT02616107
View directory record Official record
Conditions
Family Caregivers
Interventions
Managing Cancer Care: A Caregiver's Guide, Symptom Management Toolkit
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 110 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Nov 3, 2026, 1:15 PM EST
Completed Not applicable Interventional Results available

Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer

NCT00574145
View directory record Official record
Conditions
Breast Cancer, Depression, Fatigue
Interventions
Bio-field energy therapy, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment, therapeutic touch
Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Nov 3, 2026, 1:15 PM EST
Completed Phase 1 Interventional

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

NCT00928330
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
GDC-0941, Trastuzumab, trastuzumab-MCC-DM1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 3, 2026, 1:15 PM EST
Completed Phase 4 Interventional Results available

Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer

NCT02287675
View directory record Official record
Conditions
Breast Cancer
Interventions
Lymphoseek, Sulfur Colloid
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Nov 3, 2026, 1:15 PM EST
Completed Phase 2 Interventional

Raloxifene in Preventing Breast Cancer in Premenopausal Women

NCT00019500
View directory record Official record
Conditions
Breast Cancer
Interventions
raloxifene, evaluation of cancer risk factors
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
23 Years to 47 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Nov 3, 2026, 1:15 PM EST
Terminated Not applicable Interventional

The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer

NCT01351844
View directory record Official record
Conditions
Breast Cancer, Arthralgia
Interventions
Education and exercise intervention, Education and General Exercise
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Nov 3, 2026, 1:15 PM EST